Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1934190
Max Phase: Preclinical
Molecular Formula: C19H11ClN2O2
Molecular Weight: 334.76
Molecule Type: Small molecule
Associated Items:
ID: ALA1934190
Max Phase: Preclinical
Molecular Formula: C19H11ClN2O2
Molecular Weight: 334.76
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(O)c1ccc2nc(-c3ccc(Cl)cc3)c3ccncc3c2c1
Standard InChI: InChI=1S/C19H11ClN2O2/c20-13-4-1-11(2-5-13)18-14-7-8-21-10-16(14)15-9-12(19(23)24)3-6-17(15)22-18/h1-10H,(H,23,24)
Standard InChI Key: XYVLVVCDORMLTL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 334.76 | Molecular Weight (Monoisotopic): 334.0509 | AlogP: 4.80 | #Rotatable Bonds: 2 |
Polar Surface Area: 63.08 | Molecular Species: ACID | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.82 | CX Basic pKa: 3.17 | CX LogP: 3.62 | CX LogD: 0.88 |
Aromatic Rings: 4 | Heavy Atoms: 24 | QED Weighted: 0.53 | Np Likeness Score: -0.79 |
1. Haddach M, Pierre F, Regan CF, Borsan C, Michaux J, Stefan E, Kerdoncuff P, Schwaebe MK, Chua PC, Siddiqui-Jain A, Macalino D, Drygin D, O'Brien SE, Rice WG, Ryckman DM.. (2012) Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs., 22 (1): [PMID:22169261] [10.1016/j.bmcl.2011.11.087] |
Source(1):